Coronavirus vaccine research and distribution plans overlook an important, growing group: People who already got sick

Business Insider
Nov 20, 2020 · 6 min read

Experts say that without proper trial data, it’s unwise to inoculate people who were already infected, particularly if they have lingering symptoms.

Kate Bingham, the chair of the UK government’s Vaccine Taskforce, starting her Novavax trial in London.
Kate Bingham, the chair of the UK government’s Vaccine Taskforce, starting her Novavax trial at the Royal Free Hospital in London. Photo: Kirsty O’Connor/PA Images via Getty Images

By Aria Bendix

To keep reading this story, get the free app or log in.
Read the rest of this story with a free account.

You’ll also discover more fresh thinking personalized to your interests and can follow your favorite authors, publications, and topics.
Or, continue in mobile web
Already have an account? Sign in